BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 239 filers reported holding BIO-TECHNE CORP in Q2 2015. The put-call ratio across all filers is 3.05 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,423,088 | -17.0% | 35,597 | -0.5% | 0.01% | -15.4% |
| Q2 2023 | $2,920,803 | -15.3% | 35,781 | -23.0% | 0.01% | -13.3% |
| Q1 2023 | $3,448,945 | -17.2% | 46,488 | -7.6% | 0.02% | -16.7% |
| Q4 2022 | $4,167,869 | +12.6% | 50,288 | +285.9% | 0.02% | +5.9% |
| Q3 2022 | $3,701,000 | -17.9% | 13,031 | +0.2% | 0.02% | -10.5% |
| Q2 2022 | $4,508,000 | -20.0% | 13,006 | -0.1% | 0.02% | -9.5% |
| Q1 2022 | $5,637,000 | -16.3% | 13,017 | -0.0% | 0.02% | -8.7% |
| Q4 2021 | $6,736,000 | +4.1% | 13,020 | -2.5% | 0.02% | -4.2% |
| Q3 2021 | $6,472,000 | -83.4% | 13,356 | -84.6% | 0.02% | -83.0% |
| Q2 2021 | $38,933,000 | +17.9% | 86,468 | +0.0% | 0.14% | +12.8% |
| Q1 2021 | $33,015,000 | +20.7% | 86,442 | +0.4% | 0.12% | +15.7% |
| Q4 2020 | $27,349,000 | +28.2% | 86,125 | -0.0% | 0.11% | +10.2% |
| Q3 2020 | $21,337,000 | -11.9% | 86,129 | -6.1% | 0.10% | -16.2% |
| Q2 2020 | $24,209,000 | +39.6% | 91,676 | +0.3% | 0.12% | +21.9% |
| Q1 2020 | $17,337,000 | -13.6% | 91,428 | 0.0% | 0.10% | +7.9% |
| Q4 2019 | $20,069,000 | +12.4% | 91,428 | +0.2% | 0.09% | +3.5% |
| Q3 2019 | $17,861,000 | +16.8% | 91,279 | +24.4% | 0.09% | +21.1% |
| Q2 2019 | $15,295,000 | +5.1% | 73,362 | +0.1% | 0.07% | 0.0% |
| Q1 2019 | $14,546,000 | +105.3% | 73,262 | +49.6% | 0.07% | +82.1% |
| Q4 2018 | $7,086,000 | -28.8% | 48,966 | +0.4% | 0.04% | -17.0% |
| Q3 2018 | $9,952,000 | +38.2% | 48,760 | +0.2% | 0.05% | +34.3% |
| Q2 2018 | $7,199,000 | -1.7% | 48,655 | +0.4% | 0.04% | -2.8% |
| Q1 2018 | $7,320,000 | -19.0% | 48,467 | -30.5% | 0.04% | -18.2% |
| Q4 2017 | $9,035,000 | +7.6% | 69,741 | +0.4% | 0.04% | 0.0% |
| Q3 2017 | $8,398,000 | +2.9% | 69,470 | +0.1% | 0.04% | 0.0% |
| Q2 2017 | $8,158,000 | +15.5% | 69,430 | -0.1% | 0.04% | +12.8% |
| Q1 2017 | $7,062,000 | -1.2% | 69,471 | -0.0% | 0.04% | -4.9% |
| Q4 2016 | $7,145,000 | +35.8% | 69,480 | +44.6% | 0.04% | +32.3% |
| Q3 2016 | $5,263,000 | -2.8% | 48,060 | +0.1% | 0.03% | -3.1% |
| Q2 2016 | $5,414,000 | +19.4% | 48,005 | +0.1% | 0.03% | +18.5% |
| Q1 2016 | $4,533,000 | +5.4% | 47,956 | +0.3% | 0.03% | +8.0% |
| Q4 2015 | $4,301,000 | -1.3% | 47,789 | +1.4% | 0.02% | -3.8% |
| Q3 2015 | $4,358,000 | -6.1% | 47,136 | -0.0% | 0.03% | +4.0% |
| Q2 2015 | $4,643,000 | -1.8% | 47,156 | +0.1% | 0.02% | 0.0% |
| Q1 2015 | $4,726,000 | +11.6% | 47,125 | +2.8% | 0.02% | +8.7% |
| Q4 2014 | $4,235,000 | – | 45,835 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |